Cited by 138Lung Cancer Treatments and MutationsHER2/EGFR in Cancer ResearchLung Cancer Diagnosis and Treatment

The DOI matches its Crossref record; 32 of the 32 references it cites were found in a registry or an index.

Activity of Epidermal Growth Factor Receptor-Tyrosine Kinase Inhibitors in Patients with Non-small Cell Lung Cancer Harboring Rare Epidermal Growth Factor Receptor Mutations

Open access

De Pas, Tommaso, Toffalorio, Francesca, Manzotti, Michela, Fumagalli, Caterina, Spitaleri, Gianluca, Catania, Chiara, Delmonte, Angelo, Giovannini, Monica, Spaggiari, Lorenzo, de Braud, Filippo, Barberis, Massimo·2011·Journal of Thoracic Oncology

DOI 10.1097/jto.0b013e318227e8c6

Open this paper in CoChat — free account Open PDF

Abstract

Introduction Mutations of the epidermal growth factor receptor (EGFR) have been proven to predict activity of the EGFR-tyrosine kinase inhibitors (EGFR-TKI), gefitinib and erlotinib. Although the "common" EGFR mutations, such as the L858R point mutation in exon 21 and the in-frame deletional mutation in exon 19, have been definitively associated with response to EGFR-TKIs, the correlation with response to treatment for many other rarer mutations is still unclear. In this study, we report the results of treating patients with advanced non-small cell lung cancer harboring rare EGFR mutations treated with EGFR-TKIs.Methods The frequency of rare mutations has been investigated in 681 cases of non-small cell lung cancer screened between 2006 and 2010. Mutations in exons 18 and 20, uncommon mutations in exons 19 and 21, and/or the presence of different mutations in a single tumor (complex mutations) were considered rare.Results EGFR mutations were detected in 99 tumors (14.5%). Eighteen cases carried rare mutations, and 10 of these patients were treated with erlotinib or gefitinib. The clinical outcome was described case by case with references to the literature. Of note, we found two EGFR mutations never identified before and one of unknown response to EGFR-TKIs.Conclusions Gefitinib and erlotinib have different antitumor activity according to the type of the EGFR mutation borne. Report of cases harboring rare mutations can support the decision-making process in this subset of patients.

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

Integrity signals

Registry

Crossref · 10.1097/jto.0b013e318227e8c6

Cites

32 of 32 references verified0 citation errors · 0 not checkable

Statistics

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1)
Eisenhauer, E. A., Therasse, P., Bogaerts, J., Schwartz, L. H., Sargent, D., Ford, R., Dancey, J., Arbuck, S., Gwyther, S., Mooney, M., et al. (2009) · European Journal of Cancer · doi:10.1016/j.ejca.2008.10.026 · Cited by 29,534
Gefitinib or Carboplatin–Paclitaxel in Pulmonary Adenocarcinoma
Mok, T. S., Wu, Y.-L., Thongprasert, S., Yang, C.-H., Chu, D.-T., Saijo, N., Sunpaweravong, P., Han, B., Margono, B., Ichinose, Y., et al. (2009) · New England Journal of Medicine · doi:10.1056/nejmoa0810699 · Cited by 8,261
Erlotinib in Previously Treated Non–Small-Cell Lung Cancer
Shepherd, F. A., Rodrigues Pereira, J., Ciuleanu, T., Tan, E. H., Hirsh, V., Thongprasert, S., Campos, D., Maoleekoonpiroj, S., Smylie, M., Martins, R., et al. (2005) · New England Journal of Medicine · doi:10.1056/nejmoa050753 · Cited by 5,419
Gefitinib versus cisplatin plus docetaxel in patients with non-small-cell lung cancer harbouring mutations of the epidermal growth factor receptor (WJTOG3405): an open label, randomised phase 3 trial
Mitsudomi, T., Morita, S., Yatabe, Y., Negoro, S., Okamoto, I., Tsurutani, J., Seto, T., Satouchi, M., Tada, H., Hirashima, T., et al. (2010) · The Lancet Oncology · doi:10.1016/s1470-2045(09)70364-x · Cited by 4,090
Clinical and biological features associated with epidermal growth factor receptor gene mutations in lung cancers
Shigematsu, H., Lin, L., Takahashi, T., Nomura, M., Suzuki, M., Wistuba, I. I., Fong, K. M., Lee, H., Toyooka, S., Shimizu, N., et al. (2005) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/dji055 · Cited by 2,377
The T790M mutation in EGFR kinase causes drug resistance by increasing the affinity for ATP
Yun, C.-H., Mengwasser, K. E., Toms, A. V., Woo, M. S., Greulich, H., Wong, K.-K., Meyerson, M., & Eck, M. J. (2008) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0709662105 · Cited by 2,118
Erlotinib in Lung Cancer — Molecular and Clinical Predictors of Outcome
Tsao, M., Sakurada, A., Cutz, J.-C., Zhu, C., Kamel‐Reid, S., Squire, J. A., Lorimer, I. A. J., Zhang, T., Liu, G., Daneshmand, M., et al. (2005) · New England Journal of Medicine · doi:10.1056/nejmoa050736 · Cited by 1,815
Epidermal Growth Factor Receptor Gene and Protein and Gefitinib Sensitivity in Non–Small-Cell Lung Cancer
Cappuzzo, F., Hirsch, F. R., Rossi, E., Bartolini, S., Ceresoli, G. L., Bemis, L., Haney, J., Witta, S. E., Danenberg, K. D., Domenichini, I., et al. (2005) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/dji112 · Cited by 1,538
Mutations of the Epidermal Growth Factor Receptor Gene in Lung Cancer
Kosaka, T., Yatabe, Y., Endoh, H., Kuwano, H., Takahashi, T., & Mitsudomi, T. (2004) · Cancer Research · doi:10.1158/0008-5472.can-04-2818 · Cited by 1,220
Rational, biologically based treatment of EGFR-mutant non-small-cell lung cancer
Pao, W., & Chmielecki, J. (2010) · Nature Reviews Cancer · doi:10.1038/nrc2947 · Cited by 1,083

Show all 32 references

Sorted by citations

Clinical activity of afatinib in patients with advanced non-small-cell lung cancer harbouring uncommon EGFR mutations: a combined post-hoc analysis of LUX-Lung 2, LUX-Lung 3, and LUX-Lung 6
Yang, J. C.-H., Sequist, L. V., Geater, S. L., Tsai, C.-M., Mok, T. S. K., Schuler, M., Yamamoto, N., Yu, C.-J., Ou, S.-H. I., Zhou, C., et al. (2015) · The Lancet Oncology · doi:10.1016/s1470-2045(15)00026-1 · Cited by 1,002
Mechanisms of resistance to EGFR-targeted drugs: lung cancer
Morgillo, F., Della Corte, C. M., Fasano, M., & Ciardiello, F. (2016) · ESMO Open · doi:10.1136/esmoopen-2016-000060 · Cited by 476
Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor Treatment Response in Advanced Lung Adenocarcinomas with G719X/L861Q/S768I Mutations
Chiu, C.-H., Yang, C.-T., Shih, J.-Y., Huang, M.-S., Su, W.-C., Lai, R.-S., Wang, C.-C., Hsiao, S.-H., Lin, Y.-C., Ho, C.-L., et al. (2015) · Journal of Thoracic Oncology · doi:10.1097/jto.0000000000000504 · Cited by 241
Effectiveness of Gefitinib against Non–Small-Cell Lung Cancer with the Uncommon EGFR Mutations G719X and L861Q
Watanabe, S., Minegishi, Y., Yoshizawa, H., Maemondo, M., Inoue, A., Sugawara, S., Isobe, H., Harada, M., Ishii, Y., Gemma, A., et al. (2014) · Journal of Thoracic Oncology · doi:10.1097/jto.0000000000000048 · Cited by 204
A decade of EGFR inhibition in EGFR-mutated non small cell lung cancer (NSCLC): Old successes and future perspectives
Russo, A., Franchina, T., Rita Ricciardi, G. R., Picone, A., Ferraro, G., Zanghì, M., Toscano, G., Giordano, A., & Adamo, V. (2015) · Oncotarget · doi:10.18632/oncotarget.4254 · Cited by 173
Efficacy and safety of first line treatments for patients with advanced epidermal growth factor receptor mutated, non-small cell lung cancer: systematic review and network meta-analysis
Zhao, Y., Liu, J., Cai, X., Pan, Z., Liu, J., Yin, W., Chen, H., Xie, Z., Liang, H., Wang, W., et al. (2019) · BMJ · doi:10.1136/bmj.l5460 · Cited by 170
Comparison of Targeted Next‐Generation Sequencing (NGS) and Real‐Time PCR in the Detection of EGFR, KRAS, and BRAF Mutations on Formalin‐Fixed, Paraffin‐Embedded Tumor Material of Non‐Small Cell Lung Carcinoma—Superiority of NGS
Tuononen, K., Mäki‐Nevala, S., Sarhadi, V. K., Wirtanen, A., Rönty, M. J., Salmenkivi, K., Andrews, J. M., Telaranta-Keerie, A., Hannula, S., Lagström, S., et al. (2013) · Genes Chromosomes and Cancer · doi:10.1002/gcc.22047 · Cited by 164
Immunotherapy in Treating EGFR-Mutant Lung Cancer: Current Challenges and New Strategies
To, K. K. W., Fong, W., & Cho, W. C. S. (2021) · Frontiers in Oncology · doi:10.3389/fonc.2021.635007 · Cited by 157
Uncommon EGFR mutations in advanced non-small cell lung cancer
O'Kane, G. M., Bradbury, P. A., Feld, R. D., Leighl, N. B., Liu, G., Pisters, K.-M., Kamel‐Reid, S., Tsao, M., & Shepherd, F. A. (2017) · Lung Cancer · doi:10.1016/j.lungcan.2017.04.016 · Cited by 153
EGFR Exon 19 Insertions: A New Family of Sensitizing EGFR Mutations in Lung Adenocarcinoma
He, M., Capelletti, M., Nafa, K., Yun, C.-H., Arcila, M. E., Miller, V. A., Ginsberg, M. S., Zhao, B., Kris, M. G., Eck, M. J., et al. (2012) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-11-2361 · Cited by 149
The significance of epidermal growth factor receptor uncommon mutations in non-small cell lung cancer: A systematic review and critical appraisal
Gristina, V., Malapelle, U., Galvano, A., Pisapia, P., Pepe, F., Rolfo, C. D., Tortorici, S., Bazan, V., Troncone, G., & Russo, A. D. (2020) · Cancer Treatment Reviews · doi:10.1016/j.ctrv.2020.101994 · Cited by 124
Epidermal growth factor receptor tyrosine kinase (EGFR-TK) mutation testing in adults with locally advanced or metastatic non-small cell lung cancer: a systematic review and cost-effectiveness analysis
Westwood, M. E., Joore, M. A., Whiting, P. F., van Asselt, A. D. I., Ramaekers, B. L. T., Armstrong, N., Misso, K., Severens, J. L., & Kleijnen, J. (2014) · Health Technology Assessment · doi:10.3310/hta18320 · Cited by 123
Rare and complex mutations of epidermal growth factor receptor, and efficacy of tyrosine kinase inhibitor in patients with non-small cell lung cancer
Keam, B., Kim, D.-W., Park, J. H., Lee, J.-O., Kim, T. M., Lee, S.-H., Chung, D. H., & Heo, D. S. (2014) · International Journal of Clinical Oncology · doi:10.1007/s10147-013-0602-1 · Cited by 113
Uncommon Epidermal Growth Factor Receptor mutations in non-small cell lung cancer and their mechanisms of EGFR tyrosine kinase inhibitors sensitivity and resistance
Massarelli, E., Johnson, F. M., Erickson, H. S., Wistuba, I. I., & Papadimitrakopoulou, V. (2013) · Lung Cancer · doi:10.1016/j.lungcan.2013.01.018 · Cited by 110
Heterogeneous Responses to Epidermal Growth Factor Receptor (EGFR) Tyrosine Kinase Inhibitors (TKIs) in Patients with Uncommon EGFR Mutations: New Insights and Future Perspectives in this Complex Clinical Scenario
Russo, A., Franchina, T., Ricciardi, G., Battaglia, A., Picciotto, M., & Adamo, V. (2019) · International Journal of Molecular Sciences · doi:10.3390/ijms20061431 · Cited by 110
A Comparison of EGFR Mutation Testing Methods in Lung Carcinoma: Direct Sequencing, Real-time PCR and Immunohistochemistry
Angulo, B., Conde, E., Suárez‐Gauthier, A., Plaza, C., Martínez, R., Redondo, P., Izquierdo, E., Rubio‐Viqueira, B., Paz-Ares, L. G., Hidalgo, M. M., et al. (2012) · PLoS ONE · doi:10.1371/journal.pone.0043842 · Cited by 101
Examining Treatment Outcomes with Erlotinib in Patients with Advanced Non–Small Cell Lung Cancer Whose Tumors Harbor Uncommon EGFR Mutations
Klughammer, B., Brugger, W., Cappuzzo, F., Ciuleanu, T., Mok, T., Reck, M., Tan, E. H., Delmar, P., Klingelschmitt, G., Yin, A.-Y., et al. (2016) · Journal of Thoracic Oncology · doi:10.1016/j.jtho.2015.12.107 · Cited by 98
Determining EGFR-TKI sensitivity of G719X and other uncommon EGFR mutations in non-small cell lung cancer: Perplexity and solution
Li, K., Yang, M., Liang, N., & Li, S. (2017) · Oncology Reports · doi:10.3892/or.2017.5409 · Cited by 95
PD-L1 expression and T cells infiltration in patients with uncommon EGFR-mutant non-small cell lung cancer and the response to immunotherapy
Chen, K., Cheng, G., Zhang, F., Zhu, G., Xu, Y., Yu, X., Huang, Z., & Fan, Y. (2020) · Lung Cancer · doi:10.1016/j.lungcan.2020.02.010 · Cited by 89
Efficacy of EGFR tyrosine kinase inhibitors in patients with EGFR-mutated non-small cell lung cancer except both exon 19 deletion and exon 21 L858R: A retrospective analysis in Korea
Baek, J. H., Sun, J., Min, Y. J., Cho, E. K., Cho, B. C., Kim, J.-H., Ahn, M., & Park, K. (2014) · Lung Cancer · doi:10.1016/j.lungcan.2014.11.013 · Cited by 85
Therapeutic strategy for advanced EGFR mutant non-small-cell lung carcinoma
Cadranel, J. L., Ruppert, A.-M., Beau‐Faller, M., & Wislez, M. (2013) · Critical Reviews in Oncology/Hematology · doi:10.1016/j.critrevonc.2013.06.009 · Cited by 83
Distinct Epidemiology and Clinical Consequence of Classic Versus Rare EGFR Mutations in Lung Adenocarcinoma
Lohinai, Z., Hoda, M. A., Fábián, K., Ostoros, G., Rásó, E., Barbai, T., Tı́már, J., Kovalszky, I., Cserepes, M., Rózsás, A., et al. (2015) · Journal of Thoracic Oncology · doi:10.1097/jto.0000000000000492 · Cited by 79
Hope and Fear for Interferon: The Receptor-Centric Outlook on the Future of Interferon Therapy
Fuchs, S. Y. (2013) · Journal of Interferon & Cytokine Research · doi:10.1089/jir.2012.0117 · Cited by 84
EGFR–Co-Mutated Advanced NSCLC and Response to EGFR Tyrosine Kinase Inhibitors
Barnet, M. B., O'Toole, S. A., Horvath, L. G., Selinger, C. I., Yu, B., Ng, C. C., Boyer, M. J., Cooper, W. A., & Kao, S. (2016) · Journal of Thoracic Oncology · doi:10.1016/j.jtho.2016.09.001 · Cited by 77
Non-classic EGFR mutations in a cohort of Dutch EGFR-mutated NSCLC patients and outcomes following EGFR-TKI treatment
Kuiper, J. L., Hashemi, S. M. S., Thunnissen, E., Snijders, P. J. F., Grünberg, K., Bloemena, E., Sie, D., Postmus, P. E., Heideman, D. A. M., & Smit, E. F. (2016) · British Journal of Cancer · doi:10.1038/bjc.2016.372 · Cited by 73
Advances on EGFR mutation for lung cancer.
Metro, G., & Crinò, L. (2012) · Europe PMC (PubMed Central) · doi:10.3978/j.issn.2218-6751.2011.12.01 · Cited by 73
How Sensitive Are Epidermal Growth Factor Receptor–Tyrosine Kinase Inhibitors for Squamous Cell Carcinoma of the Lung Harboring EGFR Gene–Sensitive Mutations?
Hata, A., Katakami, N., Yoshioka, H., Kunimasa, K., Fujita, S., Kaji, R., Notohara, K., Imai, Y., Tachikawa, R., Tomii, K., et al. (2012) · Journal of Thoracic Oncology · doi:10.1097/jto.0b013e31827690b5 · Cited by 70
Molecular Profiling in Non–Small Cell Lung Cancer: A Step Toward Personalized Medicine
Raparia, K., Villa, C., DeCamp, M. M., Patel, J. D., & Mehta, M. P. (2013) · Archives of Pathology & Laboratory Medicine · doi:10.5858/arpa.2012-0287-ra · Cited by 68
Comparison of the effectiveness of erlotinib, gefitinib, and afatinib for treatment of non-small cell lung cancer in patients with common and rare EGFR gene mutations
Krawczyk, P., Kowalski, D. M., Ramlau, R., Kalinka-Warzocha, E., Winiarczyk, K., Stencel, K., Powrózek, T., Reszka, K., Wojas-Krawczyk, K., Bryl, M., et al. (2017) · Oncology Letters · doi:10.3892/ol.2017.5980 · Cited by 65
Resistance to EGFR inhibitors in non-small cell lung cancer: Clinical management and future perspectives
Tomasello, C., Baldessari, C., Napolitano, M., Orsi, G., Grizzi, G., Bertolini, F., Barbieri, F., & Cascinu, S. (2018) · Critical Reviews in Oncology/Hematology · doi:10.1016/j.critrevonc.2018.01.013 · Cited by 65
Clinicopathological Characteristics of 11 NSCLC Patients with EGFR-Exon 20 Mutations
Lund‐Iversen, M., Kleinberg, L., Fjellbirkeland, L., Helland, Å., & Brustugun, O. T. (2012) · Journal of Thoracic Oncology · doi:10.1097/jto.0b013e3182614a9d · Cited by 62
Cytology smears as excellent starting material for next‐generation sequencing‐based molecular testing of patients with adenocarcinoma of the lung
Павловна, В. Н., Rechsteiner, M., Wong, C. E., Zhong, Q., Rössle, M., Bode, B., Moch, H., Soltermann, A., Wild, P. J., & Tischler, V. (2016) · Cancer Cytopathology · doi:10.1002/cncy.21771 · Cited by 61
Third-Generation Tyrosine Kinase Inhibitors Targeting Epidermal Growth Factor Receptor Mutations in Non-Small Cell Lung Cancer
Barnes, T. A., O'Kane, G. M., Vincent, M. D., & Leighl, N. B. (2017) · Frontiers in Oncology · doi:10.3389/fonc.2017.00113 · Cited by 61
Clinical significance of EGFR mutation types in lung adenocarcinoma: A multi-centre Korean study
Yoon, H., Ryu, J., Sim, Y. S., Kim, D.-J., Lee, S. Y., Choi, J., Park, S., Ryu, Y. J., Lee, J. H., & Chang, J. H. (2020) · PLoS ONE · doi:10.1371/journal.pone.0228925 · Cited by 55
The Resistance to EGFR-TKIs in Non-Small Cell Lung Cancer: From Molecular Mechanisms to Clinical Application of New Therapeutic Strategies
Laface, C., Maselli, F. M., Santoro, A. N., Iaia, M. L., Ambrogio, F., Laterza, M., Guarini, C., Santis, P. D., Perrone, M., & Fedele, P. (2023) · Pharmaceutics · doi:10.3390/pharmaceutics15061604 · Cited by 63
Is there evidence for different effects among EGFR-TKIs? Systematic review and meta-analysis of EGFR tyrosine kinase inhibitors (TKIs) versus chemotherapy as first-line treatment for patients harboring EGFR mutations
Haspinger, E. R., Agustoni, F., Torri, V., Gelsomino, F., Platania, M., Zilembo, N., Gallucci, R., Garassino, M. C., & Cinquini, M. (2014) · Critical Reviews in Oncology/Hematology · doi:10.1016/j.critrevonc.2014.11.005 · Cited by 56
Outcomes of First-Generation EGFR-TKIs Against Non-Small-Cell Lung Cancer Harboring Uncommon EGFR Mutations: A Post Hoc Analysis of the BE-POSITIVE Study
Pilotto, S., Rossi, A., Vavalà, T., Follador, A., Tiseo, M., Galetta, D., Morabito, A., Di Maio, M., Martelli, O., Caffo, O., et al. (2018) · Clinical Lung Cancer · doi:10.1016/j.cllc.2017.05.016 · Cited by 46
Self-citation
Afatinib is effective in the treatment of lung adenocarcinoma with uncommon EGFR p.L747P and p.L747S mutations
Liang, S., Ko, J., Yang, J. C., & Shih, J. (2019) · Lung Cancer · doi:10.1016/j.lungcan.2019.05.019 · Cited by 46
Outcome of uncommon EGFR mutation positive newly diagnosed advanced non-small cell lung cancer patients: a single center retrospective analysis
Kate, S., Chougule, A., Joshi, A., Noronha, V., Patil, V., Dusane, R., Solanki, L., Tiwrekar, P., Trivedi, V., & Prabhash, K. (2019) · Lung Cancer Targets and Therapy · doi:10.2147/lctt.s181406 · Cited by 45
Effectiveness of tyrosine kinase inhibitors on uncommon E709X epidermal growth factor receptor mutations in non-small-cell lung cancer
Wu, J.-Y., & Shih, J.-Y. (2016) · OncoTargets and Therapy · doi:10.2147/ott.s118071 · Cited by 44
Concomitant occurrence of EGFR (epidermal growth factor receptor) and KRAS (V-Ki-ras2 Kirsten rat sarcoma viral oncogene homolog) mutations in an ALK (anaplastic lymphoma kinase)-positive lung adenocarcinoma patient with acquired resistance to crizotinib: a case report
Holten‐Rossing, H., Grauslund, M., Urbanska, E. M., Melchior, L. C., Rask, C. K., Costa, J. C., Skov, B. G., Sørensen, J. B., & Santoni‐Rugiu, E. (2013) · BMC Research Notes · doi:10.1186/1756-0500-6-489 · Cited by 44
Treatment of advanced non-small-cell lung cancer
Prabhash, K., Vora, A. D., Limaye, S. A., Sahoo, T. P., Batra, U., Patil, S., Patil, V., Noronha, V., Bhosale, B., Raut, N. V., et al. (2021) · Cancer Research Statistics and Treatment · doi:10.4103/crst.crst_61_21 · Cited by 46
Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor-sensitive Exon 19 Insertion and Exon 20 Insertion in Patients With Advanced Non–Small-cell Lung Cancer
Lin, Y.-T., Liu, Y.-N., Wu, S.-G., Yang, J. C.-H., & Shih, J.-Y. (2017) · Clinical Lung Cancer · doi:10.1016/j.cllc.2016.12.014 · Cited by 43
Management of EGFR mutated nonsmall cell lung carcinoma patients
Grigoriu, B. D., Berghmans, T., & Meert, A. (2015) · European Respiratory Journal · doi:10.1183/09031936.00156614 · Cited by 41
Osimertinib in patients with advanced epidermal growth factor receptor T790M mutation-positive non-small cell lung cancer: rationale, evidence and place in therapy
Ricciuti, B., Baglivo, S., Paglialunga, L., Giglio, A. D., Bellezza, G., Chiari, R., Crinò, L., & Metro, G. (2017) · Therapeutic Advances in Medical Oncology · doi:10.1177/1758834017702820 · Cited by 39
Pooled analysis of clinical outcome for EGFR TKI ‐treated patients with EGFR mutation‐positive NSCLC
Paz-Ares, L. G., Soulières, D., Moecks, J., Bāra, I., Mok, T. S. K., & Klughammer, B. (2014) · Journal of Cellular and Molecular Medicine · doi:10.1111/jcmm.12278 · Cited by 38
Efficacy of irreversible EGFR-TKIs for the uncommon secondary resistant EGFR mutations L747S, D761Y, and T854A
Chiba, M., Togashi, Y., Bannno, E., Kobayashi, Y., Nakamura, Y., Hayashi, H., Terashima, M., Velasco, M. A. D., Sakai, K., Fujita, Y., et al. (2017) · BMC Cancer · doi:10.1186/s12885-017-3263-z · Cited by 38
Uncommon EGFR mutations in a cohort of Chinese NSCLC patients and outcomes of first-line EGFR-TKIs and platinum-based chemotherapy
Shi, J., Department of Medical Oncology, S. P. H. &. T. C. I., Yang, H., Jiang, T., Li, X., Zhao, C., Zhang, L., Zhao, S., Liu, X., Jia, Y., et al. (2017) · Chinese Journal of Cancer Research · doi:10.21147/j.issn.1000-9604.2017.06.09 · Cited by 37
Overview on Therapeutic Options in Uncommon EGFR Mutant Non-Small Cell Lung Cancer (NSCLC): New Lights for an Unmet Medical Need
Pretelli, G., Spagnolo, C. C., Ciappina, G., Santarpía, M., & Pasello, G. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms24108878 · Cited by 39
Differences in EGFR and KRAS mutation spectra in lung adenocarcinoma of never and heavy smokers
Takamochi, K., Oh, S., & Suzuki, K. (2013) · Oncology Letters · doi:10.3892/ol.2013.1551 · Cited by 36
Non-small cell lung cancer harbouring non-resistant uncommon EGFR mutations: Mutation patterns, effectiveness of epidermal growth factor receptor-tyrosine kinase inhibitors and prognostic factors
Chang, L.-C., Lim, C., Chang, L., Chen, K., Shih, J., & Yu, C. (2019) · European Journal of Cancer · doi:10.1016/j.ejca.2019.06.025 · Cited by 35
Clinical characteristics and response to tyrosine kinase inhibitors of patients with non-small cell lung cancer harboring uncommon epidermal growth factor receptor mutations
Zhang, Y., Department of Medical Oncology, N. C. C. H., Wang, Z., Hao, X., Hu, X., Wang, H., Wang, Y., Ying, J., Department of Pathology, B. H., & Department of Pathology, N. C. C. H. (2017) · Chinese Journal of Cancer Research · doi:10.21147/j.issn.1000-9604.2017.01.03 · Cited by 35
A dramatic lung cancer course in a patient with a rare EGFR germline mutation exon 21 V843I: Is EGFR TKI resistance predictable?
Demierre, N., Zoete, V., Michielin, O. A., Stauffer, E., Zimmermann, D. R., Betticher, D. C., & Peters, S. (2013) · Lung Cancer · doi:10.1016/j.lungcan.2012.11.013 · Cited by 32
Uncommon mutation types of epidermal growth factor receptor and response to EGFR tyrosine kinase inhibitors in Chinese non-small cell lung cancer patients
Chen, K., Yu, X., Wang, H., Huang, Z., Xu, Y., Gong, L., & Fan, Y. (2017) · Cancer Chemotherapy and Pharmacology · doi:10.1007/s00280-017-3464-9 · Cited by 31
Microsecond-timescale MD simulation of EGFR minor mutation predicts the structural flexibility of EGFR kinase core that reflects EGFR inhibitor sensitivity
Yoshizawa, T., Uchibori, K., Araki, M., Matsumoto, S., Ma, B., Kanada, R., Seto, Y., Oh‐hara, T., Koike, S., Ariyasu, R., et al. (2021) · npj Precision Oncology · doi:10.1038/s41698-021-00170-7 · Cited by 28
Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors: Current Status and Future Perspectives in the Development of Novel Irreversible Inhibitors for the Treatment of Mutant Non-small Cell Lung Cancer
Galvani, E., Alfieri, R. R., Giovannetti, E., Cavazzoni, A., Monica, S. L., Galetti, M., Fumarola, C., Bonelli, M. A., Mor, M., Tiseo, M., et al. (2012) · Current Pharmaceutical Design · doi:10.2174/138161213804547222 · Cited by 30
Patients harboring uncommon EGFR exon 19 deletion-insertion mutations respond well to first-generation EGFR inhibitors and osimeritinib upon acquisition of T790M
Wang, Y., Zheng, R., Hu, P., Zhang, Z., Shen, S., & Li, X. (2021) · BMC Cancer · doi:10.1186/s12885-021-08942-x · Cited by 27
Emerging protein kinase inhibitors for non-small cell lung cancer
Liu, S. V., Subramaniam, D. S., Cyriac, G., Khalek, F. J. A., & Giaccone, G. (2013) · Expert Opinion on Emerging Drugs · doi:10.1517/14728214.2014.873403 · Cited by 28
Rare Mutations in Non-Small-Cell Lung Cancer
D’Arcangelo, M., D’Incecco, A., & Cappuzzo, F. (2013) · Future Oncology · doi:10.2217/fon.13.16 · Cited by 26
Development of a Novel, Fully-Automated Genotyping System: Principle and Applications
Suzuki, S.-I., Komori, M., Hirai, M., Ureshino, N., & Kimura, S. H. (2012) · Sensors · doi:10.3390/s121216614 · Cited by 25
Clinical Predictors of Response to EGFR Tyrosine Kinase Inhibitors in Patients with EGFR-Mutant Non-Small Cell Lung Cancer
Fukihara, J., Watanabe, N., Taniguchi, H., Kondoh, Y., Kimura, T., Kataoka, K., Matsuda, T., Yokoyama, T., & Hasegawa, Y. (2014) · Oncology · doi:10.1159/000357129 · Cited by 23
Clinical Activity of Afatinib in Patients With Non–Small-Cell Lung Cancer Harboring Uncommon EGFR Mutations: A Spanish Retrospective Multicenter Study
Morán, T., Taus, Á., Arriola, E., Aguado, C., Dómine, M., Rueda, A. G., Calles, A., Cedrés, S., Viñolas, N., Isla, D., et al. (2020) · Clinical Lung Cancer · doi:10.1016/j.cllc.2020.04.011 · Cited by 23
A Novel EGFR Mutation in Exon 19 Showed Stable Disease After TKI Treatment
van der Wekken, A. J., Stigt, J. A., & Hart, N. A. ‘. (2012) · Journal of Thoracic Oncology · doi:10.1097/jto.0b013e31825ccae8 · Cited by 21
Analysis of a large cohort of non-small cell lung cancers submitted for somatic variant analysis demonstrates that targeted next-generation sequencing is fit for purpose as a molecular diagnostic assay in routine practice
Moore, D. A., Balbi, K. J., Ingham, A., Arkenau, H., & Bennett, P. (2018) · Journal of Clinical Pathology · doi:10.1136/jclinpath-2018-205319 · Cited by 20
EGFR-RAD51 Fusion: A Targetable Partnership Originated from the Tumor Evolution?
Raez, L. E., Pinto, J. A., Schrock, A. B., & Ali, S. M. (2018) · Journal of Thoracic Oncology · doi:10.1016/j.jtho.2017.10.005 · Cited by 20
Clinical Impact of Rare and Compound Mutations of Epidermal Growth Factor Receptor in Patients With Non–Small-Cell Lung Cancer
Martin, J., Lehmann, A., Klauschen, F., Hummel, M., Lenze, D., Grohé, C., Tessmer, A., Gottschalk, J., Schmidt, B., Pau, H. W., et al. (2019) · Clinical Lung Cancer · doi:10.1016/j.cllc.2019.04.012 · Cited by 20
Clinical Benefit of Tyrosine Kinase Inhibitors in Advanced Lung Cancer with EGFR-G719A and Other Uncommon EGFR Mutations
Sehgal, K., Rangachari, D., VanderLaan, P. A., Kobayashi, S. S., & Costa, D. B. (2020) · The Oncologist · doi:10.1002/onco.13537 · Cited by 18
Use of the Ion PGM and the GeneReader NGS Systems in Daily Routine Practice for Advanced Lung Adenocarcinoma Patients: A Practical Point of View Reporting a Comparative Study and Assessment of 90 Patients
Heeke, S., Hofman, V., Long-Mira, É., Lespinet‐Fabre, V., Lalvée, S., Bordone, O., Ribeyre, C., Tanga, V., Benzaquen, J., Leroy, S., et al. (2018) · Cancers · doi:10.3390/cancers10040088 · Cited by 18
Afatinib in the first-line treatment of epidermal-growth-factor-receptor mutation-positive non-small cell lung cancer: a review of the clinical evidence
Ke, E., & Wu, Y.-L. L. C. (2016) · Therapeutic Advances in Respiratory Disease · doi:10.1177/1753465816634545 · Cited by 17
Small-cell lung cancer with a rare epidermal growth factor receptor gene mutation showing “wax-and-wane” transformation
Takagi, Y., Nakahara, Y., Hosomi, Y., & Hishima, T. (2013) · BMC Cancer · doi:10.1186/1471-2407-13-529 · Cited by 18
Mutational Portrait of Lung Adenocarcinoma in Brazilian Patients: Past, Present, and Future of Molecular Profiling in the Clinic
Freitas, H., Torrezan, G. T., da Cunha, I. W., de Macêdo, M. P., de Sá, V. K., Corassa, M. P., Ferreira, E. N., Saito, A. O., Molin, G. Z. D., de Lima, V. C. C., et al. (2020) · Frontiers in Oncology · doi:10.3389/fonc.2020.01068 · Cited by 16
Comparison of epidermal growth factor receptor tyrosine kinase inhibitors for patients with lung adenocarcinoma harboring different epidermal growth factor receptor mutation types
Park, S., Lee, S. Y., Kim, D.-J., Sim, Y. S., Ryu, J., Choi, J., Lee, S. H., Ryu, Y. J., Lee, J. H., & Chang, J. H. (2021) · BMC Cancer · doi:10.1186/s12885-020-07765-6 · Cited by 18
Clinical and molecular characteristics of epidermal growth factor receptor exon 20 insertion mutations in non-small-cell lung cancer
Geng, D., Guo, Q., Huang, S., Zhang, H., Guo, S., & Li, X. (2021) · Clinical & Translational Oncology · doi:10.1007/s12094-021-02701-x · Cited by 15
Molecular modeling and description of a newly characterized activating mutation of the EGFR gene in non-small cell lung cancer
Otto, C., Csanádi, Á., Fisch, P., Werner, M., & Kayser, G. (2012) · Diagnostic Pathology · doi:10.1186/1746-1596-7-146 · Cited by 14
Clinical outcomes of gefitinib and erlotinib in patients with NSCLC harboring uncommon EGFR mutations: A pooled analysis of 438 patients
Wang, C., Zhao, K., Hu, S., Wei, D., Gong, Y. Q., Li, M., & Xie, C. (2022) · Lung Cancer · doi:10.1016/j.lungcan.2022.08.010 · Cited by 16
The Effectiveness of Afatinib in a Patient with Advanced Lung Adenocarcinoma Harboring Rare G719X and S768I Mutations
Watanabe, M., Oizumi, S., Kiuchi, S., Yamada, N., Yokouchi, H., Fukumoto, S., & Harada, M. (2017) · Internal Medicine · doi:10.2169/internalmedicine.9565-17 · Cited by 14
Treatment of metastatic non-small cell lung cancer: 2018 guidelines of the Italian Association of Medical Oncology (AIOM)
Facchinetti, F., Pilotto, S., Metro, G., Baldini, E., Bertolaccini, L., Cappuzzo, F., Delmonte, A., Gasparini, S., Inno, A., Marchetti, A., et al. (2019) · Tumori Journal · doi:10.1177/0300891619857418 · Cited by 14
Self-citation
A novel loop‑mediated isothermal amplification method for efficient and robust detection of EGFR mutations
Horiuchi, S., Saito, Y., Matsui, A., Takahashi, N., Ikeya, T., Hoshi, E., Shimizu, Y., & Yasuda, M. (2020) · International Journal of Oncology · doi:10.3892/ijo.2020.4961 · Cited by 14
How Sensitive Are Epidermal Growth Factor Receptor–Tyrosine Kinase Inhibitors for Squamous Cell Carcinoma of the Lung Harboring EGFR Gene–Sensitive Mutations?
Hata, A., Katakami, N., & Yoshioka, H. (2014) · Journal of Thoracic Oncology · doi:10.1097/jto.0000000000000098 · Cited by 14
Treatment of advanced nonsmall cell lung cancer: First line, maintenance and second line – Indian consensus statement update
Prabhash, K. (2019) · South Asian Journal of Cancer · doi:10.4103/sajc.sajc_227_18 · Cited by 13
Highly Sensitive Droplet Digital PCR Method for Detection of de novo EGFR T790M Mutation in Patients with Non-Small Cell Lung Cancer
Wang, X., Li, X., Guo, H., Zhu, L., Peng, Z., Wang, J., Yang, F., & Guo, Y. S. (2020) · OncoTargets and Therapy · doi:10.2147/ott.s267677 · Cited by 13
Clinical outcomes of advanced non-small cell lung cancer patients harboring distinct subtypes of EGFR mutations and receiving first-line tyrosine kinase inhibitors: brain metastasis and de novo T790M matters
Zeng, Y., Guo, T., Zhou, Y., Zhao, Y., Chu, L., Chu, X., Yang, X., Ni, J., & Zhu, Z. (2022) · BMC Cancer · doi:10.1186/s12885-022-09245-5 · Cited by 13
Rare and Novel Epidermal Growth Factor Receptor Mutations in Non—Small-Cell Lung Cancer and Lack of Clinical Response to Gefitinib in Two Cases
Sharma, A., Tan, T. H., Cheetham, G., Scott, H. S., & Brown, M. P. (2012) · Journal of Thoracic Oncology · doi:10.1097/jto.0b013e31825134ac · Cited by 13
miRNAs and resistance to EGFR—TKIs in EGFR-mutant non-small cell lung cancer: beyond ‘traditional mechanisms’ of resistance
Ricciuti, B. (2015) · ecancermedicalscience · doi:10.3332/ecancer.2015.569 · Cited by 13
The Lifted Veil of Uncommon EGFR Mutation p.L747P in Non-Small Cell Lung Cancer: Molecular Feature and Targeting Sensitivity to Tyrosine Kinase Inhibitors
Yang, G., Liu, C., Hu, J., Sun, Y., Hu, P., Liu, L., Xu, H., Li, D., Li, W., Yang, Y., et al. (2022) · Frontiers in Oncology · doi:10.3389/fonc.2022.843299 · Cited by 13
Current management of uncommon EGFR mutations in non-small cell lung cancer
Trinh, J. Q., & Abughanimeh, O. K. M. (2024) · Current Problems in Cancer · doi:10.1016/j.currproblcancer.2024.101064 · Cited by 12
Rare mutations of epidermal growth factor receptor in epidermal growth factor receptor-tyrosine kinase inhibitor-naive non-small cell lung carcinoma and the response to erlotinib therapy
Sarı, M., & Aydıner, A. (2020) · Journal of Cancer Research and Therapeutics · doi:10.4103/jcrt.jcrt_757_19 · Cited by 12
Current Two EGFR Mutations in Lung Adenocarcinoma – Case Report
Svatoň, M., Pešek, M., Chudáček, J., & Vošmiková, H. (2015) · Klinicka onkologie · doi:10.14735/amko2015134 · Cited by 12
Real‐world efficacy and potential mechanism of resistance of icotinib in Asian advanced non‐small cell lung cancer with EGFR uncommon mutations: A multi‐center study
Lei, L., Wang, W., Zhu, Y., Li, J., Fang, Y., Wang, H., Zhuang, W., Zhang, Y.-B., Wang, L., Fang, M., et al. (2019) · Cancer Medicine · doi:10.1002/cam4.2652 · Cited by 12
EGFR Exon-Level Biomarkers of the Response to Bevacizumab/Erlotinib in Non-Small Cell Lung Cancer
Baty, F., Rothschild, S. I., Früh, M., Betticher, D. C., Droege, C., Cathomas, R. L., Rauch, D., Gautschi, O. P., Bubendorf, L., Crowe, S., et al. (2013) · PLoS ONE · doi:10.1371/journal.pone.0072966 · Cited by 11
Front-Line Therapy in EGFR Exon 19 Deletion and 21 Leu858Arg Mutations in Advanced Non-Small Cell Lung Cancer: A Network Meta-Analysis
Xie, T., Zou, Z., Liu, C., Zhu, Y., Xu, Z., Wang, L., Li, J., & Xing, P. (2021) · Evidence-based Complementary and Alternative Medicine · doi:10.1155/2021/9311875 · Cited by 10
The effect of EGFR‐TKIs on survival in advanced non‐small‐cell lung cancer with EGFR mutations: A real‐world study
Yu, X., Si, J., Wei, J., Wang, Y., Sun, Y. P., Jin, J., Zhang, X., Ma, T., & Song, Z. (2022) · Cancer Medicine · doi:10.1002/cam4.5413 · Cited by 11
Immunomodulatory role of oncogenic alterations in non-small cell lung cancer: a review of implications for immunotherapy
Ramos-Ramírez, M., Caballé‐Perez, E., Lucio-Lozada, J., Romero-Núñez, E., Castillo-Ruiz, C., Dorantes-Sánchez, L., Flores‐Estrada, D., Recondo, G., Barrios‐Bernal, P., Cabrera-Miranda, L. A., et al. (2025) · Cancer and Metastasis Reviews · doi:10.1007/s10555-025-10245-7 · Cited by 12
Impact of ramucirumab plus erlotinib on circulating cell-free DNA from patients with untreated metastatic non-small cell lung cancer with EGFR-activating mutations (RELAY phase 3 randomized study)
Nishio, K., Sakai, K., Nishio, M., Seto, T., Visseren‐Grul, C., Carlsen, M., Matsui, T., Enatsu, S., & Nakagawa, K. (2023) · Translational Lung Cancer Research · doi:10.21037/tlcr-22-736 · Cited by 9
Overall Survival Benefits of First-Line Treatments for Asian Patients With Advanced EGFR-Mutated NSCLC Harboring L858R Mutation: A Systematic Review and Network Meta-Analysis
Chan, S.-K., Choi, C., & Lee, V. H.-F. (2022) · JTO Clinical and Research Reports · doi:10.1016/j.jtocrr.2022.100322 · Cited by 10
Clinicopathologic characteristics and outcome of patients with different EGFR mutations
Zhou, S., Hu, X., Wang, Y., Li, J., Zhou, L., Hao, X., Liu, Y., & Shi, Y. (2018) · Asia-Pacific Journal of Clinical Oncology · doi:10.1111/ajco.13072 · Cited by 9
Antitumoral Activity of Tyrosine Kinase Inhibitors in Patients with Non-small Cell Lung Cancer Harbouring Rare Epidermal Growth Factor Receptor Mutations
Oyaert, M., Demedts, I., Boone, E., Dedeurwaerdere, F., Vandorpe, J., Laere, E. D., & Breyne, J. (2015) · Molecular Diagnosis & Therapy · doi:10.1007/s40291-015-0158-z · Cited by 9
Improved survival and intracranial tumor control of EGFR-mutated NSCLC patients with newly developed brain metastases following stereotactic radiosurgery and EGFR-TKI: a large retrospective cohort study and meta-analyses
Kuan, A. S., Chiang, C., Wu, H., Yang, H., Chen, C., Lin, C., Guo, W., Pan, D. H.-C., Chung, W., & Lee, C. (2023) · Journal of Neuro-Oncology · doi:10.1007/s11060-023-04452-x · Cited by 8
Safety and Efficacy of Osimertinib in Patients With Non–Small-Cell Lung Cancer and Uncommon Tumoral Epidermal Growth Factor Receptor Mutations: A Systematic Review and Single-Arm Meta-Analysis
Priantti, J. N., Fujiwara, Y., de Moraes, F. C. A., Michelon, I. F., Castro, C., Leighl, N. B., Cavalcante, L. L., Addeo, A., Bar, J., Horita, N., et al. (2024) · JCO Precision Oncology · doi:10.1200/po.24.00331 · Cited by 7
A Bayesian network meta-analysis of EGFR-tyrosine kinase inhibitor treatments in patients with EGFR mutation-positive non-small cell lung cancer
Yin, J., Huang, J., Ren, M., Tang, R., Xie, L., & Xue, J. (2024) · Cancer Pathogenesis and Therapy · doi:10.1016/j.cpt.2024.06.004 · Cited by 6

Authors: De Pas, T., Toffalorio, F., Manzotti, M., Fumagalli, C., Spitaleri, G., Catania, C., Delmonte, A., Giovannini, M., Spaggiari, L., de Braud, F., & Barberis, M.
Affiliations: European Institute of Oncology (IT)
University of Milan (IT)
ORCID: Toffalorio, Francesca
Fumagalli, Caterina
Spitaleri, Gianluca
Catania, Chiara
Delmonte, Angelo
Spaggiari, Lorenzo
Barberis, Massimo
Venue: Journal of Thoracic Oncology
Publisher: Elsevier BV
Published: 2011-11
Volume: 6
Issue: 11
Pages: 1895-1901
ISSN: 1556-0864 (ISSN-L)
DOI: 10.1097/jto.0b013e318227e8c6
OpenAlex: W2005728761
Cited by: 138
References: 32
Citations by year: 2026: 1 · 2025: 5 · 2024: 5 · 2023: 7 · 2022: 8 · 2021: 12 · 2020: 12 · 2019: 11 · 2018: 5 · 2017: 15 · 2016: 9 · 2015: 10 · 2014: 13 · 2013: 13 · 2012: 11
FWCI: 10.34
Type: journal article
Language: en
Open access: bronze
doi.org
Licence: www.elsevier.com/tdm/userlicense/1.0/ (tdm)
www.elsevier.com/open-access/userlicense/1.0/ (vor, 1492 d)
Locations: Journal of Thoracic Oncology (publishedVersion)
PubMed (publishedVersion)
Topics: Health Sciences › Medicine › Pulmonary and Respiratory Medicine › Lung Cancer Treatments and Mutations
Health Sciences › Medicine › Oncology › HER2/EGFR in Cancer Research
Health Sciences › Medicine › Pulmonary and Respiratory Medicine › Lung Cancer Diagnosis and Treatment
Keywords: epidermal growth factor receptor, EGFR mutation, uncommon EGFR mutations, EGFR tyrosine kinase inhibitors, gefitinib, erlotinib, non-small cell lung cancer, exon 18 mutations, exon 20 mutations, complex mutations, treatment response, predictive biomarkers
MeSH terms: Erlotinib Hydrochloride, Gefitinib, Adenocarcinoma, Adult, Aged, Aged, 80 and over, Antineoplastic Combined Chemotherapy Protocols, Carcinoma, Non-Small-Cell Lung, Female, Humans, Lung Neoplasms, Male, Middle Aged, Mutation, Neoplasm Staging, Quinazolines, Retrospective Studies, Review Literature as Topic, Treatment Outcome, ErbB Receptors

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Activity of Epidermal Growth Factor Receptor-Tyrosine Kinase Inhibitors in Patients with Non-small Cell Lung Cancer Harboring Rare Epidermal Growth Factor Receptor Mutations

Abstract

Overview

Integrity signals

Verification

Claims the paper makes

Claims other papers make about this one

Self-check

Citations

Cites

Cited by

Related

Metadata

Record

About these checks